Skip to main content

Vestibular Schwannoma

5
Pipeline Programs
9
Companies
9
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
457%
Gene Therapy
343%
+ 5 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
EndostatinPhase 2Small Molecule1 trial
Active Trials
NCT02104323Completed20Est. Apr 2016
Betta Pharmaceuticals
Betta PharmaceuticalsChina - Hangzhou
1 program
1
IcotinibPhase 2Small Molecule1 trial
Active Trials
NCT02934256Completed10Est. Jul 2018
Akouos
AkouosMA - Boston
2 programs
1
AAVAnc80-antiVEGF via Akouos Delivery DevicePhase 1/2
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene TherapyN/AGene Therapy
Prevail Therapeutics
2 programs
1
AAVAnc80-antiVEGF via Akouos Delivery DevicePhase 1/21 trial
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene TherapyN/AGene Therapy1 trial
Active Trials
NCT07503613Enrolling By Invitation100Est. Apr 2040
NCT06517888Recruiting27Est. Aug 2029
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
lapatinibPhase 1Small Molecule
Advanced Bionics
Advanced BionicsCA - Valencia
2 programs
Cochlear ImplantN/A4 trials
Cochlear Implant for Vestibular Schwannoma or Meniere DiseaseN/A
Active Trials
NCT07035873Recruiting15Est. Mar 2027
NCT06301568Completed55Est. Dec 2024
NCT05488535Completed101Est. Feb 2020
+1 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene TherapyN/AGene Therapy
AAVAnc80-antiVEGF via Akouos Delivery DevicePHASE_1_2
GSK
GSKLONDON, United Kingdom
1 program
lapatinibPHASE_1Small Molecule1 trial
Active Trials
NCT00863122Completed26Est. Aug 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Betta PharmaceuticalsIcotinib
BiocorpEndostatin
Prevail TherapeuticsAAVAnc80-antiVEGF via Akouos Delivery Device
GSKlapatinib
Prevail TherapeuticsLong Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
Advanced BionicsCochlear Implant
Advanced BionicsCochlear Implant
Advanced BionicsCochlear Implant
Advanced BionicsCochlear Implant

Clinical Trials (9)

Total enrollment: 369 patients across 9 trials

NCT02934256Betta PharmaceuticalsIcotinib

Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Start: Jul 2016Est. completion: Jul 201810 patients
Phase 2Completed
NCT02104323BiocorpEndostatin

Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Start: Jan 2014Est. completion: Apr 201620 patients
Phase 2Completed
NCT06517888Prevail TherapeuticsAAVAnc80-antiVEGF via Akouos Delivery Device

Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma

Start: Jan 2025Est. completion: Aug 202927 patients
Phase 1/2Recruiting
NCT00863122GSKlapatinib

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Start: Jun 2009Est. completion: Aug 201426 patients
Phase 1Completed
NCT07503613Prevail TherapeuticsLong Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy

Start: Mar 2026Est. completion: Apr 2040100 patients
N/AEnrolling By Invitation
NCT07035873Advanced BionicsCochlear Implant

Pediatric Cochlear Implant Remote Programming and Assessment

Start: Jan 2025Est. completion: Mar 202715 patients
N/ARecruiting
NCT06301568Advanced BionicsCochlear Implant

Retrospective Analysis of Long-term Speech Performance in Cochlear Implant Recipients Using Electro-acoustic Stimulation

Start: Jan 2024Est. completion: Dec 202455 patients
N/ACompleted
NCT05488535Advanced BionicsCochlear Implant

Non-significant Risk Study of a Cochlear Implant Headpiece

Start: Feb 2019Est. completion: Feb 2020101 patients
N/ACompleted
NCT03795675Advanced BionicsCochlear Implant

CI Following VS Removal or Labyrinthectomy

Start: Jan 2019Est. completion: Dec 202715 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 369 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.